The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations Hirotoshi Echizen Leading Article 14 September 2015 Pages: 409 - 418
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Simran D. S. MaggoRuth L. SavageMartin A. Kennedy Review Article Open access 14 September 2015 Pages: 419 - 436
Erratum to: Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Simran D. S. MaggoRuth L. SavageMartin A. Kennedy Erratum 16 February 2016 Pages: 437 - 437
Therapeutic Concentrations of Metformin: A Systematic Review Farshad KajbafMarc E. De BroeJean-Daniel Lalau Systematic Review 02 September 2015 Pages: 439 - 459
Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials Núria Buil-BrunaMaría Jesús GarridoIñaki F. Trocóniz Original Research Article 28 September 2015 Pages: 461 - 473
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA Christian WagnerYuzhuo PanPing Zhao Original Research Article 14 September 2015 Pages: 475 - 483
Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies Kai KaarnirantaKirsi IkäheimoAuli Ropo Original Research Article 21 September 2015 Pages: 485 - 494
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers Kari M. MorrisseySophie L. StockerKathleen M. Giacomini Original Research Article 27 October 2015 Pages: 495 - 506
